1
2
3
Nkarta Inc (NASDAQ)
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
交易时间表 (UTC)
开放
立即关闭
关闭日期
开幕日期
于
-
这将显示您所在时区的开放时间
(UTC)
滴答声 | NKTX |
合同价值 | 100 shares |
最大杠杆率 | 1:5 |
掉期历史
日期 | Short Swap (%) | Long Swap (%) | 无数据 |
---|
最低交易量 | 0.01 地段 |
最大交易量 | 100 地段 |
套期保值保证金 | 50% |